Physician profile
Catherine Meyerhoff
NPI 1366135410
$2,136.25
in general payments reported to CMS, 2019-2025
18 companies · $2,042 in 2025
The $2,042 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $94.50 · 2025: $2,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363.86 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $319.74 | 2025 | Farxiga, Airsupra, Breztri |
| Phathom Pharmaceuticals, INC. | $259.32 | 2025 | Voquezna |
| Lilly USA, LLC | $240.27 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $217.57 | 2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $153.05 | 2025 | Trelegy Ellipta, Shingrix |
| Sumitomo Pharma America, INC. | $114.64 | 2025 | Gemtesa |
| Exact Sciences Corporation | $84.73 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.40 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $70.90 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.82 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $44.26 | 2025 | Auvelity |
| Radius Health, INC. | $31.06 | 2025 | |
| Sonex Health, INC. | $26.56 | 2025 | Sx-One Microknife |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.12 | 2025 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.96 | 2025 | |
| Viatris Specialty LLC | $17.76 | 2025 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $15.23 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Meyerhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.